M L Bazzo1, L Golfetto1, P C Gaspar2, A F Pires2,3, M C Ramos4, M Franchini5, W A Ferreira6, M Unemo7, A S Benzaken2. 1. Molecular Biology, Microbiology and Serology Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil. 2. Department of Surveillance, Prevention and Control of Sexually Transmitted Infections, HIV/AIDS and Viral Hepatitis, Ministry of Health, Brasilia, Brazil. 3. University of Brasilia Postgraduate Program in Collective Health, Brasilia, Brazil. 4. Brazilian STD Society, Porto Alegre, Brazil. 5. Laboratory Consultant, Brasília, Brazil. 6. Alfredo da Mata Foundation, Manaus, Brazil. 7. WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Abstract
Objectives: Gonorrhoea and antimicrobial resistance (AMR) in Neisseria gonorrhoeae are major public health concerns globally. Enhanced AMR surveillance for gonococci is essential worldwide; however, recent quality-assured gonococcal AMR surveillance in Latin America, including Brazil, has been limited. Our aims were to (i) establish the first nationwide gonococcal AMR surveillance, quality assured according to WHO standards, in Brazil, and (ii) describe the antimicrobial susceptibility of clinical gonococcal isolates collected from 2015 to 2016 in all five main regions (seven sentinel sites) of Brazil. Methods: Gonococcal isolates from 550 men with urethral discharge were examined for susceptibility to ceftriaxone, cefixime, azithromycin, ciprofloxacin, benzylpenicillin and tetracycline using the agar dilution method, according to CLSI recommendations and quality assured according to WHO standards. Results: The levels of resistance (intermediate susceptibility) to tetracycline, ciprofloxacin, benzylpenicillin and azithromycin were 61.6% (34.2%), 55.6% (0.5%), 37.1% (60.4%) and 6.9% (8.9%), respectively. All isolates were susceptible to ceftriaxone and cefixime using the US CLSI breakpoints. However, according to the European EUCAST cefixime breakpoints, 0.2% (n = 1) of isolates were cefixime resistant and 6.9% (n = 38) of isolates had a cefixime MIC bordering on resistance. Conclusions: This study describes the first national surveillance of gonococcal AMR in Brazil, which was quality assured according to WHO standards. The high resistance to ciprofloxacin (which promptly informed a revision of the Brazilian sexually transmitted infection treatment guideline), emerging resistance to azithromycin and decreasing susceptibility to extended-spectrum cephalosporins necessitate continuous surveillance of gonococcal AMR and ideally treatment failures, and increased awareness when prescribing treatment in Brazil.
Objectives:Gonorrhoea and antimicrobial resistance (AMR) in Neisseria gonorrhoeae are major public health concerns globally. Enhanced AMR surveillance for gonococci is essential worldwide; however, recent quality-assured gonococcal AMR surveillance in Latin America, including Brazil, has been limited. Our aims were to (i) establish the first nationwide gonococcal AMR surveillance, quality assured according to WHO standards, in Brazil, and (ii) describe the antimicrobial susceptibility of clinical gonococcal isolates collected from 2015 to 2016 in all five main regions (seven sentinel sites) of Brazil. Methods:Gonococcal isolates from 550 men with urethral discharge were examined for susceptibility to ceftriaxone, cefixime, azithromycin, ciprofloxacin, benzylpenicillin and tetracycline using the agar dilution method, according to CLSI recommendations and quality assured according to WHO standards. Results: The levels of resistance (intermediate susceptibility) to tetracycline, ciprofloxacin, benzylpenicillin and azithromycin were 61.6% (34.2%), 55.6% (0.5%), 37.1% (60.4%) and 6.9% (8.9%), respectively. All isolates were susceptible to ceftriaxone and cefixime using the US CLSI breakpoints. However, according to the European EUCAST cefixime breakpoints, 0.2% (n = 1) of isolates were cefixime resistant and 6.9% (n = 38) of isolates had a cefixime MIC bordering on resistance. Conclusions: This study describes the first national surveillance of gonococcal AMR in Brazil, which was quality assured according to WHO standards. The high resistance to ciprofloxacin (which promptly informed a revision of the Brazilian sexually transmitted infection treatment guideline), emerging resistance to azithromycin and decreasing susceptibility to extended-spectrum cephalosporins necessitate continuous surveillance of gonococcal AMR and ideally treatment failures, and increased awareness when prescribing treatment in Brazil.
Authors: Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi Journal: Sex Health Date: 2019-09 Impact factor: 2.706
Authors: Maria Luiza Bezerra Menezes; Paulo Cesar Giraldo; Iara Moreno Linhares; Neide Aparecida Tosato Boldrini; Mayra Gonçalves Aragon Journal: Rev Soc Bras Med Trop Date: 2021-05-17 Impact factor: 1.581
Authors: Leonor Henriette de Lannoy; Roberto José de Carvalho da Silva; Edilbert Pellegrini Nahn Júnior; Eduardo Campos de Oliveira; Pâmela Cristina Gaspar Journal: Rev Soc Bras Med Trop Date: 2021-05-17 Impact factor: 1.581
Authors: Allison L Hicks; Stephen M Kissler; Tatum D Mortimer; Kevin C Ma; George Taiaroa; Melinda Ashcroft; Deborah A Williamson; Marc Lipsitch; Yonatan H Grad Journal: Elife Date: 2020-06-30 Impact factor: 8.140
Authors: Rafael Affini Martins; Dandara Cassu-Corsi; Carolina Silva Nodari; Rodrigo Cayô; Larissa Natsumeda; Ana Paula Streling; André Mario Doi; Roberto José Carvalho da Silva; Roberta Alessandra Lima Bocalon; Ana Cristina Gales; Antonio Carlos Campos Pignatari Journal: Mem Inst Oswaldo Cruz Date: 2019-08-12 Impact factor: 2.743